Literature DB >> 6407679

Cerebrotendinous xanthomatosis: biochemical response to inhibition of cholesterol synthesis.

B Lewis, W D Mitchell, C B Marenah, C Cortese, E H Reynolds, R Shakir.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6407679      PMCID： PMC1548166          DOI： 10.1136/bmj.287.6384.21-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

1.  Subcellular distribution of cerebral cholestanol in cerebrotendinous xanthomatosis.

Authors:  W L Stahl; S M Sumi; P D Swanson
Journal:  J Neurochem       Date:  1971-03       Impact factor: 5.372

2.  Cerebrotendinous xanthomatosis: reduced serum 26-hydroxycholesterol.

Authors:  N B Javitt; E Kok; B Cohen; S Burstein
Journal:  J Lipid Res       Date:  1982-05       Impact factor: 5.922

3.  Cerebrotendinous xanthomatosis: a defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid.

Authors:  H Oftebro; I Björkhem; S Skrede; A Schreiner; J I Pederson
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808
  3 in total
  4 in total

1.  Spinal form cerebrotendinous xanthomatosis patient with long spinal cord lesion.

Authors:  Ryuta Abe; Yoshiki Sekijima; Tomomi Kinoshita; Tsuneaki Yoshinaga; Shingo Koyama; Takeo Kato; Shu-Ichi Ikeda
Journal:  J Spinal Cord Med       Date:  2016-02-25       Impact factor: 1.985

2.  Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in The Netherlands.

Authors:  B J Koopman; B G Wolthers; J C van der Molen; W van der Slik; R J Waterreus; A van Spreeken
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

3.  Late-onset spinal form xanthomatosis without brain lesion: a case report.

Authors:  Masaru Yanagihashi; Osamu Kano; Tomoya Terashima; Yuji Kawase; Sayori Hanashiro; Masahiro Sawada; Yuichi Ishikawa; Nobuyuki Shiraga; Ken Ikeda; Yasuo Iwasaki
Journal:  BMC Neurol       Date:  2016-02-09       Impact factor: 2.474

4.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.